Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prothena Corporation plc - Ordinary Shares (NQ: PRTA )

13.86 +0.11 (+0.80%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 319,202
Open 13.85
Bid (Size) 13.75 (1)
Ask (Size) 15.47 (1)
Prev. Close 13.75
Today's Range 13.62 - 14.24
52wk Range 11.70 - 29.00
Shares Outstanding 45,047,449
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CrowdStrike To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Prothena Corp Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)
Via Benzinga

Performance

YTD
+1.39%
+1.39%
1 Month
-1.49%
-1.49%
3 Month
-2.05%
-2.05%
6 Month
-33.78%
-33.78%
1 Year
-49.67%
-49.67%

More News

Read More
Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights
From Prothena Corporation plc
Via Business Wire
Earnings Scheduled For February 20, 2025
Via Benzinga
Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
From Prothena Corporation plc
Via Business Wire
Deep Dive Into Prothena Corp Stock: Analyst Perspectives (5 Ratings)
Via Benzinga
Demystifying Prothena Corp: Insights From 6 Analyst Reviews
Via Benzinga
Expert Ratings For Prothena Corp
Via Benzinga
Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Prothena Announces Board of Directors Update
From Prothena Corporation plc
Via Business Wire
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease
Via Investor's Business Daily
Earnings Scheduled For November 12, 2024
Via Benzinga
Earnings Preview For Prothena Corp
Via Benzinga
Breaking Down Prothena Corp: 4 Analysts Share Their Views
Via Benzinga
Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits
Via Benzinga
Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease
From Prothena Corporation plc
Via Business Wire
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Prothena to Report Third Quarter 2024 Financial Results on November 12
From Prothena Corporation plc
Via Business Wire
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
Dow Dips 300 Points; Emcore Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Moves Higher; Prime Medicine Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Prothena Announces Leadership Team Updates
From Prothena Corporation plc
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.